40045-50-9

40045-50-9 structure

Name: SU3327
Chemical Name: 5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine
CAS Number: 40045-50-9
Molecular Formula: C₅H₃N₅O₂S₃
Molecular Weight: 261.30500
Catalog: Signaling Pathways MAPK/ERK Pathway JNK
Create Date: 2017-07-27 05:14:00
Modify Date: 2024-01-11 21:23:20
SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. SU3327 also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. SU3327 shows less active against p38α and Akt kinase[1][2].

Name	5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine
Synonyms	Loreclezole hydrochloride 2-amino-1,3,4-thiadiazole,9 SU 3327 5-[(5-nitro-1,3-thiazol-2-yl)thio]-1,3,4-thiadiazol-2-amine 5-(5-nitrothiazol-2-ylthio)-1,3,4-thiadiazol-2-amine 5-(5-nitro-thiazol-2-ylsulfanyl)-[1,3,4]thiadiazol-2-ylamine (amino-5 thiadiazol-1,3,4-yl-2) thio-2 nitro-5 thiazole 2-Amino-5-(5-nitrothiazol-2-yl)mercapto-1,3,4-thiadiazole

Description	SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. SU3327 also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. SU3327 shows less active against p38α and Akt kinase[1][2].
Related Catalog	Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease Signaling Pathways >> MAPK/ERK Pathway >> JNK
Target	IC50: 0.7 μM (JNK); 239 nM (JNK-JIP interactions)[1]
In Vitro	SU3327 (compound 9) is able to inhibit TNF-α stimulated phosphorylation of c-Jun in HeLa cells (EC50 = 6.23 μM)[1]. SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1[3].
In Vivo	SU3327 (Compound 9; 25 mg/kg; intraperitoneal injection; male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes[1]. SU3327 (Compound 9) has favorable microsomal and plasma stability (T1/2 = 27 min)[1]. Animal Model: Male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice (11-week-old ) injected with insulin[1] Dosage: 25 mg/kg Administration: Intraperitoneal injection Result: Resulted in a statistically significant reduction in blood glucose levels.
References	[1]. De SK, et al. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem. 2009 Apr 9;52(7):1943-52. [2]. Augustine C, et al. Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro. Neuroscience. 2014 Aug 22;274:1-10. [3]. Serizawa F, et al. Pretreatment of human cerebrovascular endothelial cells with CO-releasing molecule-3 interferes with JNK/AP-1 signaling and suppresses LPS-induced proadhesive phenotype. Microcirculation. 2015 Jan;22(1):28-36.

Density	1.888g/cm3
Boiling Point	549.841ºC at 760 mmHg
Melting Point	160 °C(dec.)
Molecular Formula	C₅H₃N₅O₂S₃
Molecular Weight	261.30500
Flash Point	286.334ºC
Exact Mass	260.94500
PSA	193.02000
LogP	2.08950
Index of Refraction	1.793

3034-48-8

2349-67-9

~92%

40045-50-9

Literature: Bourdais; Dauvillier; Gayral; et al. European Journal of Medicinal Chemistry, 1981 , vol. 16, # 3 p. 233 - 239

Precursor 2
3034-48-8 2349-67-9
DownStream 0

56-41-7	108-65-6
56-35-9	64-17-5
67-56-1	108-88-3
141-78-6	1310-73-2
13463-67-7	1333-86-4